Melanoma Matters25 Juni 2025

Ep 70: Best of ASCO colon.... 2025 ;)

You wanted it, we gave it... best of ASCO ...colon...2025 :D

In this episode, hosts James and Sapna discuss the key highlights from ASCO 2025, focusing on significant abstracts related to melanoma treatment. They delve into the implications of adrenal insufficiency, the 5 year, final results of Lifileucel, and the ongoing debate between neoadjuvant and adjuvant therapies. The conversation also explores the role of IL-6 in treatment efficacy and the importance of understanding sentinel lymph node positivity. The hosts emphasize the need for innovative clinical trial designs to adapt to emerging data and improve patient outcomes.

Keywords

ASCO 2025, melanoma, neoadjuvant therapy, adrenal insufficiency, lifileucel, immunotherapy, clinical trials, IL-6, treatment outcomes, cancer research

Chapters

00:00 Introduction and Overview of ASCO 2025

03:16 DoorDash!

05:43 Key Highlights from ASCO 2025

08:29 Lifileucel and Its Impact on Treatment

10:53 Long-term Outcomes and Toxicity Considerations

15:49 Exploring Treatment Efficacy in Refractory Populations

17:41 Neoadjuvant and Adjuvant Therapies: A Comparative Analysis

21:07 Investigating GM-CSF's Role in Mitigating Toxicity

22:36 RELA 098: Insights and Implications

25:37 Understanding Sentinel Lymph Node Positivity in Melanoma

26:34 Future Directions in Neoadjuvant Therapy Research

36:18 Fact Check

38:17 Discussion on IPI GM-CSF and Adrenal Insufficiency

42:09 Impact of Adrenal Insufficiency on Patients

45:06 Future Directions in Neoadjuvant Trials

47:26 Wrap-Up and Reflections

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(93)

Ep 88: Negative Adjuvant Doublet Studies (CM915, KV010, RELA098)

Melanoma Matters: Why Adjuvant Doublet Immunotherapy Fell ShortHobbies - James wishes he was surfing more This episode breaks down three negative adjuvant melanoma trials testing combination immunothe...

1 Sep 22min

Ep 86: Teaser Tudriqev (RP1) FDA Approval

James asks the big question

25 Aug 10s

Ep 87: INTerpath-001 Press Release - August 2026

In this episode, Sapna and James discuss the INTerpath-001 press release describing primary endpoint (RFS) and key secondary endpoint (DMFS) findings from the randomized phase 3 study of individualize...

25 Aug 12min

Ep 86: Tudriqev (RP1) FDA Approval

In this episode, James and Sapna debate how to pronounce the newest FDA approved treatment for melanoma: T-U-D-R-I-Q-E-VThey discuss the FDA Cell and Gene Therapy Advisory Committee's review of the si...

25 Aug 52min

Ep 85: Surgical considerations for TIL

In this episode, Sapna and James talk tv shows - The Gambler and His Cowboys, Brassic... They discuss the paper from NKI on surgical considerations for TIL harvest published in BJS in 2025. Topics of ...

28 Juli 29min

Ep 84: Merlin CP-GEP and Castle i31-SLNB tests

In this episode, the chin dimple is front and center. James explains the wizarding home of Tintagel in Cornwall to Sapna, situated on a lovely promontory. This episode explores the latest evidence on ...

24 Juli 35min

Ep 83: Guest Megan Othus and Time of Day Administration

James and Sapna welcome Megan Othus, Professor of Biostatistics at the Fred Hutch Cancer Center and one of the key statisticians at SWOG.Megan talks about growing up in the PNW and going East to get b...

24 Juni 40min

Ep 82: Best of ASCO: 2026

In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications.They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, f...

13 Juni 1h 4min